“Committed to making the difference”
AiCuris is a pharmaceutical company focused on the discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.
Founded in 2006 as a spin-out from Bayer's virology and bacteriology research department, AiCuris is now an established “powerhouse for anti-infectives” and is one of the few biotech companies world-wide to have successfully brought a drug to market, and therefore to patients (Prevymis® 2017/18).
Today AiCuris has an innovative pipeline of anti-infective agents and a team of internationally recognized scientists in Research and Development. By focusing on therapeutic areas with high medical need, the company is positioned for growth and success.
Cooperation with Lysando
|AiCuris and Lysando join forces in the fight against antimicrobial resistance|
Lysando AG and AiCuris today annouced the signing of a long-term cooperation for the development and optimization of Artilysin®-based drug candidates for various anti-bacterial indications.
Investment in Wuppertal
|AiCuris plans its further growth in Wuppertal and intends investing millions at the site|
Investments amounting to several million euros are planned over the next few years for the modernisation and expansion of the premises and laboratories.